摘要
目的本研究旨在评价多西他赛单药或联合奥沙利铂二线治疗晚期非小细胞肺癌（NSCLC）的疗效和安全性。方法将57例ⅢB期或Ⅳ期的一线治疗失败的NSCLC患者分成多西他赛联合奥沙利铂组（27例）（多西他赛60mg／m2，第1天静脉输注＋奥沙利铂100mg／m2，第2天静脉输注）和多西他赛单药组（30例）（多西他赛75mg／m2，第1天静脉输注），均为3周方案，每例患者接受2～6个周期治疗，评价疗效及不良反应。结果联合治疗组和多西他赛单药组疾病控制率分别为70．4％和43．3％（P=0．04），中位无进展生存期分别为5．2个月和3．6个月（P=0．03），中位生存时间分别为9．8个月和7．2个月（P=0．06）。而在主要的3～4级毒副反应中，联合治疗组和多西他赛单药组比较，差异均无统计学意义。结论多西他赛联合奥沙利铂二线治疗NSCLC取得了较好的疗效，毒副反应可以耐受，值得进一步研究。
Objective To evaluate the efficacy and safety of docetaxel/oxaliplatin and docetaxel as second-line chemotherapy for advanced non-small cell lung cancer （NSCLC）. Methods Fifty-seven patients with previously treated advanced NSCLC had divided into docetaxel/oxaliplatin group （docetaxel 60 mg/m2 on 1st day with oxaliplatin 100 mg/m2 on 2nd day, every three weeks） and doxetaxel group （75 mg/m2 on 1st day, every three weeks）. All patients who received 2-6 cycles could be evaluated. Results There were statistical differences between docetaxel/oxaliplatin group and docetaxel group in the disease control rate （70.4% vs 43.3%, P ：0.04）, the median progression-free survival （5.2 months vs 3.6 months, P =0.03）, but no statistical differences in the median overall survival （9.8 months vs 7.2 months, P =0.06）. In addition,there were statistical differences in the main grade 3-4 toxicity between two groups. Conclusions Docetaxel/oxaliplatin is an effective and well-tolerated scheme in the treatment of advanced NSCLC, which warrant further evaluation as second-line therapy for patients with NSCLC.
出处
《国际呼吸杂志》
2013年第8期573-576,共4页
International Journal of Respiration
关键词
非小细胞肺癌
奥沙利铂
多西他赛
化疗
Non-small cell lung cancer
Oxaliplatin
Docetaxel
Chemotherapy
